DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer

Molecular Oncology

Volumn 10, Issue 6, 2016, Pages 879-894

  Kurfurstova, Daniela ^a   Bartkova, Jirina ^b,c   Vrtel, Radek ^a   Mickova, Alena ^a   Burdova, Alena ^a   Majera, Dusana ^a   Mistrik, Martin ^a   Kral, Milan ^a   Santer, Frederic R ^d   Bouchal, Jan ^a   Bartek, Jiri ^a,b,c  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

DNA damage response barrier; NQO1 and oxidative stress; P53 and NKX3.1 tumour suppressors; PARP inhibitor biomarkers; Prostate tumorigenesis; TMPRSS2 ERG

Indexed keywords

53BP1 PROTEIN; 8 HYDROXYGUANINE; ATM PROTEIN; BIOLOGICAL MARKER; CYCLIN D1; HISTONE H2AX; JMJD1C PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NQO1 PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; REV7 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; NQO1 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; FUSION GENE; GENE REARRANGEMENT; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TMPRSS2 ERG FUSION GENE; AGED; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); ONCOGENE PROTEINS, FUSION; OXIDATIVE STRESS; PROSTATE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 84960540174     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.02.005     Document Type: Article

References (66)

1. Ahn K.S., Sethi G., Jain A.K., Jaiswal A.K., Aggarwal B.B. Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J. Biol. Chem. 2006, 281:19798-19808.
2. Anders C.K., Winer E.P., Ford J.M., Dent R., Silver D.P., Sledge G.W., Carey L.A. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin. Cancer Res. 2010, 16:4702-4710.
3. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., Isaacs C., Kvale P.A., Reding D.J., Weissfeld J.L., Yokochi L.A., O'Brien B., Ragard L.R., Clapp J.D., Rathmell J.M., Riley T.L., Hsing A.W., Izmirlian G., Pinsky P.F., Kramer B.S., Miller A.B., Gohagan J.K., Prorok P.C. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J. Natl. Cancer Inst. 2012, 104:125-132.
4. Anwar A., Dehn D., Siegel D., Kepa J.K., Tang L.J., Pietenpol J.A., Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J. Biol. Chem. 2003, 278:10368-10373.
5. Aparicio A., Den R.B., Knudsen K.E. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat. Rev. Urol. 2011, 8:562-568.
6. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A 2001, 98:1188-1193.
7. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 1996, 8:805-814.
8. Bartek J., Iggo R., Gannon J., Lane D.P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990, 5:893-899.
9. Bartek J., Lukas J. DNA repair: cyclin D1 multitasks. Nature 2011, 474:171-172.
10. Bartkova J., Hamerlik P., Stockhausen M.T., Ehrmann J., Hlobilkova A., Laursen H., Kalita O., Kolar Z., Poulsen H.S., Broholm H., Lukas J., Bartek J. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010, 29:5095-5102.
11. Bartkova J., Hoei-Hansen C.E., Krizova K., Hamerlik P., Skakkebaek N.E., Rajpert-De M.E., Bartek J. Patterns of DNA damage response in intracranial germ cell tumors versus glioblastomas reflect cell of origin rather than brain environment: implications for the anti-tumor barrier concept and treatment. Mol. Oncol. 2014, 8:1667-1678.
12. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
13. Bartkova J., Horejsi Z., Sehested M., Nesland J.M., Rajpert-De M.E., Skakkebaek N.E., Stucki M., Jackson S., Lukas J., Bartek J. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007, 26:7414-7422.
14. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Orntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
15. Beyer R.E., Segura-Aguilar J., Di B.S., Cavazzoni M., Fato R., Fiorentini D., Galli M.C., Setti M., Landi L., Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. U. S. A 1996, 93:2528-2532.
16. Bouchal J., Santer F.R., Hoschele P.P., Tomastikova E., Neuwirt H., Culig Z. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. Prostate 2011, 71:431-437.
17. Bouwman P., Aly A., Escandell J.M., Pieterse M., Bartkova J., van der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., Haffty B.G., Tommiska J., Blomqvist C., Drapkin R., Adams D.J., Nevanlinna H., Bartek J., Tarsounas M., Ganesan S., Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17:688-695.
18. Bowen C., Ju J.H., Lee J.H., Paull T.T., Gelmann E.P. Functional activation of ATM by the prostate cancer suppressor NKX3.1. Cell Rep. 2013, 4:516-529.
19. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., Patel S., Wang X., Liang H., Yu J., Palanisamy N., Siddiqui J., Yan W., Cao X., Mehra R., Sabolch A., Basrur V., Lonigro R.J., Yang J., Tomlins S.A., Maher C.A., Elenitoba-Johnson K.S., Hussain M., Navone N.M., Pienta K.J., Varambally S., Feng F.Y., Chinnaiyan A.M. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
20. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., Maestro R., Pelicci P.G., d'Adda di F.F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
21. Ding Z., Wu C.-J., Chu G.C., Xiao Y., Ho D., Zhang J., Perry S.R., Labrot E.S., Wu X., Lis R., Hoshida Y., Hiller D., Hu B., Jiang S., Zheng H., Stegh A.H., Scott K.L., Signoretti S., Bardeesy N., Wang Y.A., Hill D.E., Golub T.R., Stampfer M.J., Wong W.H., Loda M., Mucci L., Chin L., DePinho R.A. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
22. Dinkova-Kostova A.T., Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 2010, 501:116-123.
23. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004, IARCPress, Lyon.
24. Ergen H.A., Gormus U., Narter F., Zeybek U., Bulgurcuoglu S., Isbir T. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer. Anticancer Res. 2007, 27:4107-4110.
25. Evangelou K., Bartkova J., Kotsinas A., Pateras I.S., Liontos M., Velimezi G., Kosar M., Liloglou T., Trougakos I.P., Dyrskjot L., Andersen C.L., Papaioannou M., Drosos Y., Papafotiou G., Hodny Z., Sosa-Pineda B., Wu X.R., Klinakis A., Orntoft T., Lukas J., Bartek J., Gorgoulis V.G. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ. 2013, 20:1485-1497.
26. Fagerholm R., Hofstetter B., Tommiska J., Aaltonen K., Vrtel R., Syrjakoski K., Kallioniemi A., Kilpivaara O., Mannermaa A., Kosma V.M., Uusitupa M., Eskelinen M., Kataja V., Aittomaki K., von S.K., Heikkila P., Lukas J., Holli K., Bartkova J., Blomqvist C., Bartek J., Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1 2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 2008, 40:844-853.
27. Felgueiras J., Silva J.V., Fardilha M. Prostate cancer: the need for biomarkers and new therapeutic targets. J. Zhejiang Univ. Sci. B 2014, 15:16-42.
28. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
29. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
30. He J., Kang X., Yin Y., Chao K.S.C., Shen W.H. PTEN regulates DNA replication progression and stalled fork recovery. Nat. Commun. 2015, 6:7620.
31. Howat W.J., Wilson B.A. Tissue fixation and the effect of molecular fixatives on downstream staining procedures. Methods 2014, 70:12-19.
32. Iggo R., Gatter K., Bartek J., Lane D., Harris A.L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990, 335:675-679.
33. Iskander K., Gaikwad A., Paquet M., Long D.J., Brayton C., Barrios R., Jaiswal A.K. Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res. 2005, 65:2054-2058.
34. Jaamaa S., Af Hallstrom T.M., Sankila A., Rantanen V., Koistinen H., Stenman U.H., Zhang Z., Yang Z., De Marzo A.M., Taari K., Ruutu M., Andersson L.C., Laiho M. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res. 2010, 70:8630-8641.
35. Jackson S.P., Bartek J. The DNA damage response in human biology and disease. Nature 2009, 461:1071-1078.
36. Jirawatnotai S., Hu Y., Michowski W., Elias J.E., Becks L., Bienvenu F., Zagozdzon A., Goswami T., Wang Y.E., Clark A.B., Kunkel T.A., van H.T., Xia B., Correll M., Quackenbush J., Livingston D.M., Gygi S.P., Sicinski P. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011, 474:230-234.
37. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
38. Kelsey K.T., Ross D., Traver R.D., Christiani D.C., Zuo Z.F., Spitz M.R., Wang M., Xu X., Lee B.K., Schwartz B.S., Wiencke J.K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 1997, 76:852-854.
39. Kim G., Ison G., McKee A.E., Zhang H., Tang S., Gwise T., Sridhara R., Lee E., Tzou A., Philip R., Chiu H.J., Ricks T.K., Palmby T., Russell A.M., Ladouceur G., Pfuma E., Li H., Zhao L., Liu Q., Venugopal R., Ibrahim A., Pazdur R. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 2015, 21:4257-4261.
40. Kolar Z., Burdova A., Jamaspishvili T., Bouchal J., Kucerova R., Bienova M., Kral M., Student V. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2beta expression to TMPRSS2-ERG fusion status in prostate cancer. Neoplasma 2014, 61:9-16.
41. Kosova F., Temeltas G., Ari Z., Lekili M. Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients. Tumour. Biol. 2014, 35:4295-4299.
42. Long D.J., Waikel R.L., Wang X.J., Perlaky L., Roop D.R., Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 2000, 60:5913-5915.
43. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
44. Lukas J., Lukas C., Bartek J. More than just a focus: the chromatin response to DNA damage and its role in genome integrity maintenance. Nat. Cell Biol. 2011, 13:1161-1169.
45. Malins D.C., Johnson P.M., Wheeler T.M., Barker E.A., Polissar N.L., Vinson M.A. Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res. 2001, 61:6025-6028.
46. Mateo J., Carreira S., Sandhu S., Miranda S., Mossop H., Perez-Lopez R., Nava R.D., Robinson D., Omlin A., Tunariu N., Boysen G., Porta N., Flohr P., Gillman A., Figueiredo I., Paulding C., Seed G., Jain S., Ralph C., Protheroe A., Hussain S., Jones R., Elliott T., McGovern U., Bianchini D., Goodall J., Zafeiriou Z., Williamson C.T., Ferraldeschi R., Riisnaes R., Ebbs B., Fowler G., Roda D., Yuan W., Wu Y.M., Cao X., Brough R., Pemberton H., A'Hern R., Swain A., Kunju L.P., Eeles R., Attard G., Lord C.J., Ashworth A., Rubin M.A., Knudsen K.E., Feng F.Y., Chinnaiyan A.M., Hall E., de Bono J.S. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 2015, 373:1697-1708.
47. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.S., Waldman T., Lord C.J., Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1:315-322.
48. Miyake H., Hara I., Kamidono S., Eto H. Oxidative DNA damage in patients with prostate cancer and its response to treatment. J. Urol. 2004, 171:1533-1536.
49. Schiewer M.J., Knudsen K.E. Transcriptional roles of PARP1 in cancer. Mol. Cancer Res. 2014, 12:1069-1080.
50. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Zappa M., Nelen V., Kwiatkowski M., Lujan M., Maattanen L., Lilja H., Denis L.J., Recker F., Paez A., Bangma C.H., Carlsson S., Puliti D., Villers A., Rebillard X., Hakama M., Stenman U.H., Kujala P., Taari K., Aus G., Huber A., van der Kwast T.H., van Schaik R.H., de Koning H.J., Moss S.M., Auvinen A. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, 384:2027-2035.
51. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence. Histopathology 2012, 60:199-215.
52. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
53. Shevde L.A., Samant R.S. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014, 37:131-141.
54. Siegel D., Anwar A., Winski S.L., Kepa J.K., Zolman K.L., Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 2001, 59:263-268.
55. Siegel D., Bolton E.M., Burr J.A., Liebler D.C., Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol. Pharmacol. 1997, 52:300-305.
56. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 2004, 65:1238-1247.
57. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
58. Steinbrecher A., Rohrmann S., Timofeeva M., Risch A., Jansen E., Linseisen J. Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2010, 19:135-143.
59. Steiner M., Hillenbrand M., Borkowsi M., Seiter H., Schuff-Werner P. 609 C--> T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett. 1999, 135:67-71.
60. Stoehr C.G., Nolte E., Wach S., Wieland W.F., Hofstaedter F., Hartmann A., Stoehr R. NAD(P)H:quinone oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in Caucasians. Int. J. Mol. Sci. 2012, 13:10959-10969.
61. Thapa D., Meng P., Bedolla R.G., Reddick R.L., Kumar A.P., Ghosh R. NQO1 suppresses NF-kappaB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res. 2014, 74:5644-5655.
62. Tort F., Bartkova J., Sehested M., Orntoft T., Lukas J., Bartek J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res. 2006, 66:10258-10263.
63. Watanabe S., Watanabe K., Akimov V., Bartkova J., Blagoev B., Lukas J., Bartek J. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat. Struct. Mol. Biol. 2013, 20:1425-1433.
64. Williams J.L., Greer P.A., Squire J.A. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. Cancer Genet. 2014, 207:474-488.
65. Xu G., Chapman J.R., Brandsma I., Yuan J., Mistrik M., Bouwman P., Bartkova J., Gogola E., Warmerdam D., Barazas M., Jaspers J.E., Watanabe K., Pieterse M., Kersbergen A., Sol W., Celie P.H.N., Schouten P.C., van den Broek B., Salman A., Nieuwland M., de Rink I., de Ronde J., Jalink K., Boulton S.J., Chen J., van Gent D.C., Bartek J., Jonkers J., Borst P., Rottenberg S. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015, 521:541-544.
66. Zimmermann M., Lottersberger F., Buonomo S.B., Sfeir A., de Lange T. 53BP1 regulates DSB repair using Rif1 to control 5' end resection. Science 2013, 339:700-704.